PMID- 28704306
OWN - NLM
STAT- MEDLINE
DCOM- 20180622
LR  - 20181202
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Linking)
VI  - 70
IP  - 5
DP  - 2017 Nov
TI  - Reversal of Ticagrelor-Induced Arrhythmias and Cheyne-Stokes Respiration With 
      Aminophylline Infusion.
PG  - 290-292
LID - 10.1097/FJC.0000000000000518 [doi]
AB  - Dyspnea and bradyarrhythmias are frequent adverse effects (AEs) of ticagrelor. 
      AEs commonly occur within the first week of therapy, are dose related and usually 
      mild, but sometimes they may cause drug discontinuation. Currently, the exact 
      mechanisms of ticagrelor-related AEs have not been definitively explained. In 
      addition to the prevalent theory of adenosine overload, other reasonable 
      mechanism like a direct central stimulation hypothesis was suggested. We present 
      a case of incessant Cheyne-Stokes respiration associated with heart rate 
      instability in patient with congestive heart failure and non-ST-segment elevation 
      myocardial infarction, supporting the use of aminophylline as a potential 
      reversal agent of ticagrelor-related AEs.
FAU - Conte, Lorenzo
AU  - Conte L
AD  - *UO Malattie Cardiovascolari, Ospedale Santa Croce, Castelnuovo di Garfagnana, 
      Italy; daggerDipartimento di Patologia Medica, Chirurgica, Molecolare e dell'Area 
      Critica, Universita di Pisa, Pisa, Italy; and double daggerFondazione Toscana Gabriele 
      Monasterio, Pisa, Italy.
FAU - Pugliese, Nicola R
AU  - Pugliese NR
FAU - Giannoni, Alberto
AU  - Giannoni A
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - 27Y3KJK423 (Aminophylline)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
SB  - IM
MH  - Adenosine/adverse effects/*analogs & derivatives
MH  - Aged
MH  - Aminophylline/*administration & dosage
MH  - Arrhythmias, Cardiac/*chemically induced/*drug therapy/physiopathology
MH  - Cardiotonic Agents/administration & dosage
MH  - Cheyne-Stokes Respiration/*chemically induced/*drug therapy/physiopathology
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Phosphodiesterase Inhibitors/administration & dosage
MH  - Purinergic P2Y Receptor Antagonists/adverse effects
MH  - Ticagrelor
EDAT- 2017/07/14 06:00
MHDA- 2018/06/23 06:00
CRDT- 2017/07/14 06:00
PHST- 2017/07/14 06:00 [pubmed]
PHST- 2018/06/23 06:00 [medline]
PHST- 2017/07/14 06:00 [entrez]
AID - 10.1097/FJC.0000000000000518 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2017 Nov;70(5):290-292. doi: 
      10.1097/FJC.0000000000000518.